31 January 2019
Every year, more than 300,000 patients acquire infections in hospitals and GP surgeries in England, many of which are resistant to antibiotics and extremely difficult to treat. At STFC’s Daresbury Laboratory, start-up company Chemical Intelligence is developing revolutionary technology that is set to play a key role in in preventing the thousands of potentially life threatening antibiotic-resistant infections each year.
The company’s internationally patented technology, which was developed in association with the University of Nottingham, involves a unique anti-microbial molecule that is activated when it comes into contact with light and oxygen. The technique prevents the spread of bacteria to and from surfaces and people, killing deadly microbes including E.coli and the MRSA superbug. Last year the company launched the world’s first medical examination gloves to have built-in anti-microbial technology that can kill up to 99.9 per cent of bacteria in less than five minutes of contact.
Chemical Intelligence is the latest company to take advantage of the world-class R&D facilities for start-ups at Daresbury Laboratory, where it is now looking to further the development of this completely unique anti-microbial technology for use in other high volume, disposable, consumable medical devices.
Founder and CEO, Rob Gros said: “With the emergence of new resistant bacteria and superbugs, the need for innovation to help prevent the spread of infections is only going to grow. Our mission is to make our anti-microbial medical examination gloves an industry standard in hospitals across the world, whilst we continue to develop this technology for other medical products. For Chemical Intelligence, carrying out our essential R&D at Daresbury Laboratory provides us with valuable access to a technologically sophisticated research environment within which we can innovate as quickly and cost-effectively as possible as we work towards achieving our business goals.”
Delyth Edwards, business development manager, at STFC, said: “Chemical Intelligence is developing technology that has the ability to both save lives and relieve the financial burden on health care authorities. However, developing innovative new products for healthcare applications can be a long and challenging process, and I’m thrilled that Daresbury Laboratory is providing the right R&D environment and support for Chemical Intelligence as it takes its exciting new technology to the next level.”
Further information about support for SMEs at Daresbury Laboratory and across STFC more generally, can be found on our business incubation page.
Last updated: 31 January 2019